期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

贝伐单抗治疗晚期大肠癌的研究进展 被引量：2

下载PDF
导出
摘要 血管内皮生长因子(VEGF)是目前已知作用最强的促血管形成因子,因而是抗血管生成治疗的主要靶点。贝伐单抗是抗VEGF受体的人源单克隆抗体,可抑制肿瘤血管生成,目前用于一线治疗大肠癌。
作者 陈日新 逯华
机构地区 广西柳州市人民医院肿瘤科
出处 《现代肿瘤医学》 CAS 2009年第1期178-180,共3页 Journal of Modern Oncology
关键词 血管内皮生长因子 贝伐单抗 大肠癌
分类号 R735 [医药卫生—肿瘤] R730.54 [医药卫生—肿瘤]
  • 相关文献

参考文献17

  • 1Yancapoulos GD, Davis S, Gale NW, et al. Vascular specific growth factors and blood vessel formation [ J ]. Nature, 2000, 407 : 242 - 248.
  • 2Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor - induced angiogenesis suppresses tumour growth in vivo[J]. Nature, 1993, 362:841 -844.
  • 3De Castro Junior G, Puglisi F, De Azambuja E, et al. Angiogenesis and cancer: A cross - talk between basic science and clinical trials(the " do utdes" paradigm) [ J]. Crit Rev Oncol Hematol, 2006, 59 ( 1 ) : 40 - 50.
  • 4Jain RK. Normalization of tumor vasculature : an emerging concept in antiangiogenic therapy[J]. Science, 2005, 307 (5706): 58- 62.
  • 5Wang Y, Fei D, Vanderlaan M, et al. Biological activity of bevacizumab,a humannized anti -VEGF antibody in vitro[J]. Angiogenesis, 2004, 7(4): 335-345.
  • 6封宇飞,雷静,傅得兴.血管内皮生长因子抑制剂——贝伐单抗[J].中国药学杂志,2005,40(19):1519-1520. 被引量：10
  • 7Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase Ⅱ, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin(LV) with FU/LV alone in patients with metastatic colorectal cancer[ J ]. J Clin Oncol, 2003,21 ( 1 ) : 60 -65.
  • 8Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. N Engl J Med, 2004, 350(23): 2335 -2342.
  • 9Kabbinavar FF, Schulz J, Mccleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first - line metastatic colorectal cancer: Results of a randomized phase Ⅱ trial [ J ]. J Clin Oncol, 2005, 23(16) :3697 -3705.
  • 10Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy:The addition of bevacizumab to fluorouracil/leucovorin imptoves survival for patients with metastatic colorectal cancer[J]. J Clin Oncol,2005,23(16) :3706 -3712.

二级参考文献10

  • 1Zondor SD, Medina PJ.Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies [ J ] . Ann Pharmacoth,2004, 38(7-8): 1258.
  • 2Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy[ J]. Oncologist, 2004, 9(Suppl 1): 2.
  • 3Hsei VC, Novotny WF, Margolin K, et al.Population pharmacokinetic (PK) analysis of bevacizumab(BV) in cancer subjects(abstract)[J].Proc Am Soc Clin Oncol, 2001, 20: 69a.
  • 4Gorden MS, Margolin K, Talpaz M, et al.Phase Ⅰ safety and pharmacokintic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer[J]. J Clin Oncol, 2001, 19:843.
  • 5FDA, AVASTINTM[DB/OL], http:/www.fda, gov/cder/foi/label/2004/12/1250581bl .pdf, 2004-08-11
  • 6Hurwitz H, Fehrenbacher L, Novotny W, et al.Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J] .N Engl J Med ,2004 , 350(23):2335.
  • 7Kabbinavar F, Hurwitz HI, Fehrenbacher L, etal, Phase Ⅱ, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin(LV) with FU/LV alone in patients with metastatic colorectal cancer[J]. J Clin Oncol , 2003, 21(1):60.
  • 8Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phaseⅡ trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer [ J ] . J Clin Oncol ,2004, 22(11):2184.
  • 9Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias:therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab [ J ]. Clin Cancer Res, 2004, 10 ( 11 ):3577.
  • 10Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer[ J ] . N Engl J Me, 2003, 349 (5): 427.

共引文献9

同被引文献13

引证文献2

二级引证文献15

现代肿瘤医学
2009年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部